Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 28, 2024

Femasys Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-40492	11-3713499
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3950 Johns Creek Court, Suite 100 Suwanee, Georgia		30024
(Address of principal executive offices)		(Zip Code)

(770) 500-3910

(Registrant’s telephone number, including area code)

n/a

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		FEMY		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 7.01

Regulation FD Disclosure

On February 28, 2024, Femasys Inc. (the “Company”) posted on its website an updated slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

The information furnished in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as may be expressly set forth by specific reference in such filing.

The Company expressly disclaims any obligation to update or revise any of the information contained in the corporate presentation.

Item 8.01

Other Events

On February 28, 2024, Femasys Inc. (the “Company”) issued a press release announcing FemaSeed FDA clearance brings timely access to a first-line infertility treatment option as an alternative to IVF. A copy of the press release is being furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.	Description

99.1	Femasys Inc. Corporate Presentation dated February 28, 2024
99.2	Press Release of Femasys Inc. dated February 28, 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Femasys Inc.

	By:	/s/ Kathy Lee-Sepsick
	Names: Kathy Lee-Sepsick
	Title: Chief Executive Officer

Date: February 28, 2024

Exhibit 99.1

Disrupting Convention in Women’s Health Through Continuous Innovation February 2024 Corporate Presentation 1

Forward-Looking Statements This Presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations and financial conditions, including but not limited to current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, results of clinical trials and other future conditions. Words such as, but not limited to, "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "potential", "predict", "project", "should", "will", "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, identify forward-looking statements. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Presentation and are subject to risks and uncertainties. Moreover, the Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for management to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The Company qualifies all of the forward-looking statements in this Presentation by these cautionary statements. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Statements contained herein are made as of the date of this Presentation unless stated otherwise, and neither this Presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that the information will be updated or revisited to reflect information that subsequently becomes available or changes occurring after that date hereof. Certain information contained in this Presentation relates to or is based on statistical and other industry and market data obtained from independent industry publications and research, surveys and studies conducted by independent third parties as well as the Company's own estimates. The market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. The Company's estimates of the total addressable market of the patient population with the potential to benefit from treatment with any product candidates the Company may develop, our ability to commercialize our product candidates, or the effect of delays in commercializing include several key assumptions based on its industry knowledge, industry publications and third-party research, which may be based on a small sample size and may fail to accurately reflect the addressable patient population. While the Company believes that its internal assumptions are reasonable, no independent source has verified such assumptions. This Presentation contains trademarks, trade names, or service marks belonging to other entities. The Company does not intend the use or display of other parties' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of, or by these other parties. 2

Femasys’ Mission has Remained the Same Despite Significant Market Changes Who We Are Financial Information Femasys is focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions. Femasys is poised to navigate the ever-changing landscape of women’s health by enabling choice and empowering women. Headquarters: Suwanee, GA Nasdaq: FEMY (IPO June 2021) Market Cap: $35M (as of 02/27/24) Cash: $23M (as of 11/15/23) 3

Investment Highlights Differentiator 4 Develop disruptive approaches for women’s health Address multi-billion-dollar global market opportunities Limited competition with clear reimbursement path Improved patient care and health economics Intellectual property portfolio with >150 patents globally Cash runway into Q2 2025 Woman-founded and led, experienced leadership team Commercial-readiness with in-house CMC and device manufacturing Global regulatory approvals, including the U.S., Japan, and Canada Mission Foundation

Key Leadership Brian Drumheller VP, Quality 30+ years of experience Dan Currie Chief Operating Officer 30+ years of experience Jeremy Sipos VP, Research & Development 20+ years of experience Christine Thomas SVP, Regulatory & Clinical 20+ years of experience Chris Johansen VP, Manufacturing 20+ years of experience James Liu, MD Chief Medical Officer 40+ years of experience Mary An Merchant, JD, PhD VP Counsel, Intellectual Property 25+ years of experience Dov Elefant Chief Financial Officer 25+ years of experience 5 Kathy Lee-Sepsick President, CEO, Founder 25+ years of experience Richard Spector Chief Commercial Officer 25+ years of experience

FemBloc® Product Candidate Research Preclinical Stage ISafety Stage IIValidation Stage IIIPivotal Our Technologies Provide a Continuum of Care 6 In-office, minimally invasive solutions that share delivery platforms. Commercially Available Products Commercially Available Products FemaSeed® Treatment Intratubal Insemination FemVue® Diagnostic Contrast-Generating Device FemCath® Diagnostic Selective Delivery Catheter FemCerv® Diagnostic Endocervical Tissue Sampler Permanent Birth Control Clinical Trial

FemaSeed® Intratubal Artificial Insemination 7 Innovative first-line infertility treatment designed to deliver sperm directly where conception occurs First in-office ultrasound evaluation of fallopian tubes Infertility Focused Portfolio FemVue® Tubal Diagnosis with Ultrasound FDA-Cleared in U.S. and Approved in Canada

No New Affordable Options for Infertility in Decades 8 https://www.cdc.gov/nchs/nsfg/key_statistics/i-keystat.htm Kumar N, et al. (2015) Levine H. et al. (2023) Centers for Disease Control and Prevention (2019) Chandra A, et al. (2014) Key Trends: 43 U.S. states have recorded lowest fertility rate in last three decades4 9.14 million women have received infertility services at some time in their lives5 >10M women struggle with infertility1 ~50% due to male factor2 Sperm counts worldwide have declined by >50%3

4.3M seek evaluation only FemaSeed and FemVue Advanced as Less Costly Options 9 Diagnosis Discussion Drugs IUI IVF PATIENT JOURNEY *Centers for Disease Control and Prevention. 2019 Assisted Reproductive Technology Fertility Clinic and National Summary Report. US Dept of Health and Human Services; 2021. ~200k cycles/ year in U.S. ~1 M cycles/ year in U.S.* ~ 90% couples with male factor infertility For female, multiple invasive procedures, medical risks and impact on quality of life.

FemaSeed and FemVue Advanced as Less Costly Options 10 Diagnosis Discussion Drugs IUI IVF FemVue FemaSeed PATIENT JOURNEY Safe Time-saving Affordable Convenient ~200k cycles/ year in U.S. ~1 M cycles/ year in U.S.* *Centers for Disease Control and Prevention. 2019 Assisted Reproductive Technology Fertility Clinic and National Summary Report. US Dept of Health and Human Services; 2021.

Femasys’ Product Portfolio from Diagnosis to Treatment 11 First In-office, Ultrasound Approach for Fallopian Tube Evaluation Video will open in browser window. Allows for selective evaluation when needed Contrast generated allows for diagnosis of tube FemVue intended population: Baseline diagnostic test for infertility (blocked tubes are a silent factor affecting 1 in 3 infertile women) Open fallopian tube(s) should be established prior to any infertility treatment.

Femasys’ Product Portfolio from Diagnosis to Treatment 12 Video will open in browser window. Video will open in browser window. Delivers sperm to where conception occurs First Intratubal Insemination Approach without Catheterization FemaSeed intended population: Infertile women/ couples Patients desiring insemination, including same sex couples & single women FemaSeed requires at least one open fallopian tube (FemVue can be performed first to confirm)

13 FemaSeed Overcomes the Last Barrier to Natural Fertilization Sperm must travel from vagina to the fallopian tube where conception occurs. Vagina Cervix Uterus FemaSeed IUI Fallopian Tube - Reproductive Endocrinologist HCP* - Reproductive Endocrinologist HCP* - Reproductive Endocrinologist HCP* FemaSeed Advantages from Market Research *Femasys proprietary market research (100 reproductive endocrinologists). It’s angle toward the opening (ostia) is the most critical finding that I am impressed with that allows sperm to be the closest to the egg. It’s an interesting concept for women who have unilateral disease [blocked tube]. “ Delivery to fallopian tube makes sense with low count [sperm] cases to improve efficacy. ” ” “ “ ” 92% of Survey Respondents had favorable impression of FemaSeed* ”

14 “Being aware that there are many reasons why women have issues conceiving, FemVue is one easy procedure that can assist in finding out why it may have been difficult. As such, I highly recommend any woman who has tried for months or years to conceive to get the FemVue procedure. It is a procedure that will get you immediate results for you and your doctor to discuss the next steps of making your dreams come true.” “After a month of completing successful medical procedures including FemVue, my husband and I conceived our first child.” “For more than 20 years, current approaches to infertility treatment have been limited during the initial stage of therapeutic care, but with the advancement of FemaSeed, we believe a next generation intrauterine procedure may have the opportunity to truly change this traditional paradigm.” The Unmet Need in Infertility: Compelling Testimonials - Michael Glassner, MD Founding Partner and Medical Director of Main Line Fertility & Reproductive Medicine FemaSeed Physician Testimonial FemVue Patient Testimonials

Commercialization Strategy in U.S. 15 Initial Focus ~1,700 Infertility Specialists ~40,000 Gynecologists Limited Market Release Focused regions and targeted audience Focused sales and marketing efforts Monitoring, evaluation and iterative improvement Expanded Market Release Wider distribution and geographical expansion Targeted marketing and sales strategies Education and training Expanded product offerings Customer support, feedback collection and monitoring market performance Expanded Focus

FemaSeed Priced to Support First-Line Treatment Option 16 IUI Intrauterine Insemination FemaSeed $500-$4,0001 total per cycle including ultrasound monitoring, and optional ovulation drugs2 + device per cycle above IUI cost Average Total Cost 1https://www.fertilityiq.com/iui-or-artificial-insemination/the-cost-of-iui 2Parenthood, Planned. “What Is Intrauterine Insemination (IUI)?” Planned Parenthood, https://www.plannedparenthood.org/learn/pregnancy/fertility-treatments/what-iui. 3Ravitsky, et al. The forgotten men: rising rates of male infertility urgently require new approaches for its prevention, diagnosis and treatment. Biology of Reproduction, 2019, 101(5), 872-874. IVF/ ICSI In vitro fertilization / intracytoplasmic sperm injection $30,000 total per cycle, including ultrasound monitoring, ovulation drugs, egg extraction and freezing3 Population If insurance, covered under IUI codes (service, sperm washing) Insurance with positive coverage policy typically covers 3-6 cycles Required prior to IVF/ ICSI in many coverage policies Infertile Women/ Couples Seeking Treatment Subset of Infertile (After 1-3 IUI cycles or as indicated) Intratubal Insemination (FDA cleared as form of an IUI) Reimbursement 14/20 covered states that have fertility insurance coverage, include IVF

FemaSeed has Significant Potential Revenue Opportunity 17 Market Expansion opportunity $2B 1 million* IUI cycles/ yr Addressable market opportunity 4.8 millionwomen seek evaluation & treatment Market immediate addressable Future patients *Centers for Disease Control and Prevention. 2019 Assisted Reproductive Technology Fertility Clinic and National Summary Report. US Dept of Health and Human Services; 2021 4.3 millionseek evaluation only

FemBloc® Permanent Birth Control 18 First and only non-surgical, in-office, permanent birth control option In late-stage clinical development with on-going multi-center pivotal trial (FINALE) Potential to be the safest and most natural approach at substantially less cost than the long-standing surgical alternative In-Office Sterilization Lead Product Candidate

>100 Years of Stagnant Innovation for Permanent Birth Control $20B total market expansion 19 *Frattarelli 2007 >13M women no longer intend to have children >12M use non-permanent birth control long-term $2B annual market opportunity 800,000 women choose surgical tubal ligation as a form of permanent birth control every year*

FemBloc: Expected Competitive Advantages Permanent Birth Control Temporary FemBloc Surgical Sterilization (94% effective*) Essure® No longer marketed (95% effective*) IUD Permanent ✔ ✔ ✔ Office Procedure ✔ Some ✔ No Special Capital Equipment ✔ ✔ No Anesthesia ✔ ✔ No Permanent Implant (coil/ clip) ✔ No Surgery (risks/ cost) ✔ ✔ No Hormones ✔ ✔ ✔ One-Time Treatment Cost ✔ ✔ ✔ Multiple IUDs Worldwide Applicability ✔ Varies ✔ 20 *Fertility and Sterility, 2022

No Permanent Implant – Scar Tissue Closes Tubal Lumen FemBloc Treatments FemBloc: In-Office Procedure followed by Ultrasound Confirmation Test Balloon at tubal opening without cannulation Biopolymer is designed to be expelled within 3 months Biopolymer solidifies 21 Video will open in browser window. Biopolymer degrades Confirmation Test (to ensure success) Video will open in browser window.

Completed Earlier FemBloc Supportive Studies (N=321) Stage I: Safety (N=183); IDE approved FemBloc Clinical Studies for Pre-Market Approval (PMA) 22 Stage III: FINALE Pivotal Clinical Trial Trial Design (IDE approved June 2023; currently enrolling) Prospective, multi-center, open-label, single-arm study Roll-in study design (50 subjects in part A for safety) Endpoints: Primary: pregnancy rate at 1-year after using FemBloc (N=401) Secondary: safety and various in-office assessments Additional Analysis: 2-5 years post-market for safety Interim analysis: after 300 women have used FemBloc for 1-year Selection of Confirmation Test for Pivotal Stage II: Validation (N=45); IDE approved Early Clinical (N=93) Long-Term Safety with No Serious AEs Reported Evaluated Delivery & Biopolymer

FemBloc Safety Profile (N = 228 subjects from Stage I & II; 5-year follow-up on-going) 23 Other Key Findings: Investigator Rating: 96% extremely or very satisfied with FemBloc Most common AEs: 59% bleeding/ spotting 55% pain/ cramps Mean pain score per visual analog scale (0-10): 4.6 FemBloc 3.4 confirmation test 61% 8% 16% 3% 0.5% 5% 4% 0.5% 0.8% No SAEs 91% AEs related to device/procedure occurred within 7 days of procedure FemBloc Treatment Timing of AEs

FemBloc Improves Health Economics Permanent One-Time Cost Breakdown Pre-Op $6,000* Facility Anesthesia Post-Op Cost of FemBloc System Anesthesia Physician / Practice FemBloc estimate < ½ cost of Tubal Ligation Physician In-office procedure expands practice services Can perform multiple procedures in same room Quick to perform; ease of room turnover Patient resumes normal activities Expect 3 reimbursable visits FemBloc Efficiencies *Planned Parenthood 2019, https://www.plannedparenthood.org/learn/birth-control;Doximity 2019; U.S. Bureau of Labor Statistics, 2019. 24 NO COST TO PATIENT (covered under Affordable Care Act)

Upcoming Anticipated Milestones Near term expected valuation inflection points creating accretive value for investors. 25 Q1 Q2 Q3 Q4 Top line data for FemaSeed pivotal clinical trial (LOCAL) Initial commercial team on-boarded Limited market release of infertility product portfolio in North America Achieve CE mark for infertility product portfolio Expand market release of infertility product portfolio to additional regions in North America Femasys Milestones

Investment Highlights Differentiator 26 Develop disruptive approaches for women’s health Address multi-billion-dollar global market opportunities Limited competition with clear reimbursement path Improved patient care and health economics Intellectual property portfolio with >150 patents globally Cash runway into Q2 2025 Woman-founded and led, experienced leadership team Commercial-readiness with in-house CMC and device manufacturing Global regulatory approvals, including the U.S., Japan, and Canada Mission Foundation

Disrupting Convention in Women’s Health Through Continuous Innovation February 2024 Corporate Presentation Investors: IR@femasys.com Contact: Media: Media@femasys.com 27 03333 R08

Exhibit 99.2

Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

-- Femasys readies for the commercial launch of FemaSeed^® in the U.S. amidst the uncertainty following the Alabama Supreme Court Ruling on how to handle embryos used for in vitro fertilization (IVF) --

-- Femasys to announce top-line data from recently completed pivotal clinical trial for FemaSeed in first quarter 2024 --

ATLANTA, February 28, 2024 -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today highlighted that its FemaSeed intratubal insemination product, a revolutionary approach to enhancing fertilization, is expected to serve as a first-line therapeutic option that is substantially lower cost with significantly less risk than assisted reproductive methods, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). FemaSeed has been designed to deliver sperm reliably and safely, directly into the fallopian tube where conception occurs.

“Femasys remains committed to providing accessible and affordable options and the timing of FemaSeed’s launch is particularly relevant given the uncertainty following the Alabama Supreme Court ruling on February 16^th. Following our substantial cash infusion in the fourth quarter 2023, we are now funded into the second half of 2025 and on track to make FemaSeed, available later this year to women and their doctors, as a first-line treatment option that does not involve handling of embryos,” said Femasys’ CEO Kathy Lee-Sepsick.

About FemaSeed

FemaSeed^® is an innovative infertility treatment designed to deliver sperm to the fallopian tube where conception occurs. It is intended to enhance natural fertilization and provide a first-line treatment option for those seeking pregnancy. FemaSeed is less invasive and more affordable than assisted reproduction procedures, such as IVF or ICSI. In 2023, FemaSeed achieved U.S. FDA clearance (September) and regulatory approval in Canada (April) for patients seeking insemination. At the end of the fourth quarter of 2023, Femasys completed a pivotal clinical trial (“LOCAL” trial) for those seeking intratubal insemination with a specific focus on male factor infertility, a contributing factor in approximately 40-50% of infertility cases. Top line data from this study is planned for release first quarter 2024 and will support the commercial launch targeted for the first half of 2024.

About Femasys

Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead revolutionary product candidate and FDA-cleared, innovative therapeutic and diagnostic products. Femasys’ FemBloc^® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. Femasys’ FemaSeed^® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. The Company’s diagnostic products include FemVue^® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath^®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv^®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our product candidates; our ability to commercialize our product candidates, or the effect of delays in commercializing; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

Contacts:

Investors

Chuck Padala

LifeSci Advisors, LLC

917-741-7792

chuck@lifesciadvisors.com

Femasys Inc.

Investor Contact:

IR@femasys.com

Media Contact:

Media@femasys.com

Document and Entity Information	Feb. 28, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Feb. 28, 2024
Entity File Number	001-40492
Entity Registrant Name	Femasys Inc.
Entity Central Index Key	0001339005
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3713499
Entity Address, Address Line One	3950 Johns Creek Court
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Suwanee
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30024
City Area Code	770
Local Phone Number	500-3910
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	FEMY
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false